HIMSHims & Hers Health, Inc.
What is the market doing?
No clear lean: in an uptrend, but a crowded short (+23% of shares).
In an uptrend, above its rising 50- and 200-day averages. Price is +12% vs its 200-day average.
Insiders were net sellers over the 90 days ending Oct 8, 2026; selling is often routine (taxes, diversification).
A crowded short, settled Sep 15, 2026, about a week of normal trading to cover. Down 3.7% since the previous count, down from 28.7% of shares outstanding three months ago.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. Insider selling is often routine (taxes, diversification); only cluster buying is a strong tell.
How HIMS is trading
Hims & Hers Health, Inc. is −47% over the past year while the S&P 500 is +18%: 65 points behind the market. Through the fall, its own insiders bought $1.2M more stock than they sold.
1-year return · S&P 500 +18%
- vs 200-day average
- +12%
vs 200-day average · a clear uptrend
- RSI (14)
- 57
RSI (14) · neutral
- Below its 52-week high
- 51%
Below its 52-week high
Details›
- Last close2026-10-09
- $30.88
- 1 monthS&P 500 +2.7%
- +13%
- 1 yearS&P 500 +18%
- −47%
- 5 yearsS&P 500 +88%
- +257%
- vs 50-day average$29.43
- +4.9%
- 52-week high
- $62.76
- 52-week low
- $14.52
- Annualised volatility
- 103%
- Insider buying, net, 6 monthsForms 3/4/5 to 2026-10-08
- $1.2M
| Year | Return |
|---|---|
| 2026 (year to date) | −4.9% |
| 2025 | +34% |
| 2024 | +172% |
| 2023 | +39% |
| 2022 | −2.1% |
| 2021 | −55% |
| 2020 | +47% |
| Month | Years | Positive | Average |
|---|---|---|---|
| Jan | 7 | 4 of 7 | +9.9% |
| Feb | 7 | 4 of 7 | +6.6% |
| Mar | 7 | 3 of 7 | +1.1% |
| Apr | 7 | 3 of 7 | +1.9% |
| May | 7 | 3 of 7 | +16% |
| Jun | 7 | 5 of 7 | +1.8% |
| Jul | 7 | 4 of 7 | +4.8% |
| Aug | 7 | 3 of 7 | −12% |
| Sep | 7 | 4 of 7 | +7.0% |
| Oct | 8 | 3 of 8 | −6.0% |
| Nov | 7 | 5 of 7 | +19% |
| Dec | 7 | 3 of 7 | −0.15% |
End-of-day closes from IEX; the S&P 500 comparison uses SPY over the same window. Prices are a reference point, not a basis for trading decisions.
Drug Manufacturers, Specialty & Generic
Ranks #36 of 41 by RyuScore